Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 118

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 118
---
 $1.3 million, after deducting offering expenses payable by us, (iv) the issuance and sale      
 of 10,925,000 Common Shares in the Third November 2025 Offering at a public offering price of $0.25 per Common Share for net proceeds    
 of approximately $2.1 million, after deducting offering expenses payable by us, (v) the issuance and sale of 10,810,828 Common Shares    
 and/or pre-funded warrants in the Fourth November 2025 Offering at a public offering price of $0.12 per Common Share and $0.1199         
 per pre-funded warrant for net proceeds of approximately $1.3 million, after deducting offering expenses payable by us, (vi) the         
 issuance and sale of 16,000,000 Common Shares in the December 2025 Offering at a public offering price of $0.10 per Common Share         
 for net proceeds of approximately $1.55 million, after deducting offering expenses payable by, and (vii) the issuance of 2,090,987       
 Common Shares for aggregate gross proceeds of approximately $183,000 as a result of the exercise of warrants to purchase 2,894,769       
 Common Shares for cash and on a cashless basis issued in our financings in April 2023 and January 2024, as if such events had occurred   
 on July 31, 2025.                                                                                                                        |

You should read this information in conjunction with our consolidated financial statements and the related notes appearing at the end of this prospectus and the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section and other financial information contained in this prospectus.

|                                      |     | As of  July 31, 
 2025            |         |   |     |       |         |   |
|:-------------------------------------|:----|:----------------|--------:|:--|:----|:------|--------:|:--|
| U.S. dollars in thousands            |     | Actual          |         |   |     | Pro   
 Forma |         |   |
| Cash and cash equivalents            |     | $               |   3,495 |   |     | $     |  12,925 |   |
| Derivative warrants liability        |     |                 |  (2,179 | ) |     |       |  (1,782 | ) |
| Shareholders’ equity:                |     |                 |         |